Septerna (NASDAQ:SEPN) Stock Price Down 8.5% – What’s Next?

Septerna, Inc. (NASDAQ:SEPN) traded down 8.5% during mid-day trading on Friday . The company traded as low as $18.91 and last traded at $19.08. 45,386 shares changed hands during trading, a decline of 71% from the average session volume of 158,137 shares. The stock had previously closed at $20.85.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SEPN. TD Cowen began coverage on Septerna in a research note on Tuesday, November 19th. They set a “buy” rating for the company. Wells Fargo & Company began coverage on Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price objective for the company. JPMorgan Chase & Co. began coverage on Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $50.00 price objective for the company.

Septerna Price Performance

The firm has a fifty day simple moving average of $23.70.

Insider Buying and Selling

In other Septerna news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the stock in a transaction on Monday, October 28th. The shares were purchased at an average cost of $18.00 per share, with a total value of $6,669,000.00. Following the completion of the transaction, the insider now directly owns 6,215,591 shares of the company’s stock, valued at $111,880,638. This represents a 6.34 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.